Clay Siegall’s Mission to Impact Treatment

The CEO and founder of Seattle Genetics, Clay Siegall has been putting his fingerprint on the business world for quite some time. Siegall and his biotech team are focused on developing quality drugs to treat diseases that have high death rates. The company is client centered and determined to improve the health of people across the world.

Clay Siegall is a graduate of The University of Maryland where he received a degree in zoology. He would later earn a Ph.D in genetics from George Washington University. Siegall founded his company in 1998 and has been a tremendous leader during that time. Siegall has guided Seattle Genetics to the top the therapy industry. His company was the first to develop the FDA-approved drug conjugate. Furthermore the company has developed a collection of more than twenty drugs. During this time they have been able to establish relationships with some major drug manufactures including Bayer,Pfizer and several others.

Siegall’s business got started in a unique way. He has always had an interest in in medicine and technology. He became interested in cancer treatment while studying at the University of Maryland. This interest stemmed from a family member that got sick with cancer. He became aware of alternate, radical treatments that had the potential of being effective. This sparked his interest and ultimately served as the birth of his new company.

Clay Siegall’s resume has become quite impressive over the years. Outside of being the founder of Seattle Genetics, Siegall has collaborated with the Bristol-Myers Squibb Pharmaceutical Research Institute during the early 1990’s. He has also worked with the he National Cancer Institute and National Institutes of Health. Siegall’s success has allowed him to serve the Board of Directors of Alder BioPharmaceuticals. He has become an accomplished author published in more than 70 publications. He is an inventor also, holding fifteen patents. His work is admired by many and should continue making an impact for years to come.